arrow
M

Michael Weber

University of British Columbia
H指数:71
被引数:1.8万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Reassessing the minimal clinically important differences of patient-reported outcomes in cervical myelopathy a patient-centered approach from the Canadian Spine Outcomes and Research Network

重新评估颈髓病中患者报告结果的最小临床重要差异:来自加拿大脊柱结局与研究中心的患者中心方法

2026-03-010
PRE
PSMA-Directed PET/MRI Enables Noninvasive Diagnosis and Prognosis in Patients with Increased PSA Levels: Results from the Prospective Randomized RAPID Trial

PSMA导向的PET/MRI可在PSA水平升高的患者中实现非侵入性诊断和预后评估:来自前瞻性随机RAPID试验的结果

2026-02-011
PRE
CTNI-06. UPDATE FROM THE LONG-TERM FOLLOW-UP (LTFU) PHASE OF RENEU: A PIVOTAL PHASE 2B TRIAL OF MIRDAMETINIB IN CHILDREN AND ADULTS WITH NEUROFIBROMATOSIS TYPE 1 (NF1)-ASSOCIATED SYMPTOMATIC PLEXIFORM NEUROFIBROMA (PN)

CTNI-06. RENEU长期随访(LTFU)阶段的更新:一项关于Mirdametinib在患有神经纤维瘤病1型(NF1)相关症状性丛状神经纤维瘤(PN)的儿童和成人中的关键性2B期试验

2025-11-110
OA
UNDERSTANDING COMMONLY REPORTED (≥15%) TREATMENT-RELATED ADVERSE EVENTS IN THE RENEU TRIAL OF MIRDAMETINIB IN CHILDREN AND ADULTS WITH NEUROFIBROMATOSIS TYPE 1 (NF1)-ASSOCIATED PLEXIFORM NEUROFIBROMA (PN)

理解MIRDAMETINIB在RENEU试验中针对神经纤维瘤病1型(NF1)相关丛状神经纤维瘤(PN)的儿童和成人患者中常见报告的(≥15%)治疗相关不良事件

2025-11-010
OAAI
EXPLORING THE RELATIONSHIP BETWEEN PATIENT BASELINE CHARACTERISTICS WITH RESPONSES TO MIRDAMETINIB IN THE RENEU TRIAL OF CHILDREN AND ADULTS WITH NEUROFIBROMATOSIS TYPE 1 (NF1)-ASSOCIATED PLEXIFORM NEUROFIBROMA (PN)

探索RENEU试验中,儿童和成人神经纤维瘤病1型(NF1)相关丛状神经纤维瘤(PN)患者基线特征与Mirdametinib反应之间的关系

2025-11-010
OAAI
RENEU LONG-TERM FOLLOW-UP (LTFU) UPDATE: A PIVOTAL, PHASE 2B TRIAL OF MIRDAMETINIB IN CHILDREN AND ADULTS WITH NEUROFIBROMATOSIS TYPE 1 (NF1)-ASSOCIATED SYMPTOMATIC PLEXIFORM NEUROFIBROMA (PN)

RENEU长期随访(LTFU)更新:一项关于Mirdametinib在患有1型神经纤维瘤病(NF1)相关症状性丛状神经纤维瘤(PN)的儿童和成人中的关键性、2B期试验

2025-10-010
OAAI
68Ga-DOTATATE PET/CT versus MRI in neuroendocrine liver metastases: a comprehensive per-lesion analysis

68Ga-DOTATATE PET/CT与MRI在神经内分泌肝脏转移瘤中的比较:一项全面的病灶级分析

2025-09-110
PRE
MRI-derived quantification of hepatic vessel-to-volume ratios in chronic liver disease using a deep learning approach

利用深度学习方法对慢性肝病中肝脏血管体积比进行MRI衍生定量分析

2025-08-120
OAAI
Enhancing MRI efficiency in musculoskeletal examinations: Impact of optimized facility design and workflow optimization efforts

提高 musculoskeletal 检查中 MRI 效率:优化设施设计和流程优化工作的影晌

2025-06-230
PRE
HEALTH-RELATED QUALITY-OF-LIFE (HRQOL) IN ADULTS AND CHILDREN WITH NEUROFIBROMATOSIS TYPE 1-ASSOCIATED PLEXIFORM NEUROFIBROMA (NF1-PN) TREATED WITH MIRDAMETINIB: PIVOTAL, PHASE 2B RENEU TRIAL
2024-11-110
PRE